Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Bellera, C.A.; Penel, N.; Ouali, M.; Bonvalot, S.; Casali, P.G.; Nielsen, O.S.; ... ; Mathoulin-Pelissier, S. (2015)

Article / Letter to editor

• guidelines
• randomized controlled trial
• time-to-event end point
• efficacy measure
• sarcoma
• gastrointestinal stromal tumors

• All authors: Bellera, C.A.; Penel, N.; Ouali, M.; Bonvalot, S.; Casali, P.G.; Nielsen, O.S.; Delannes, M.; Litiere, S.; Bonnetain, F.; Dabakuyo, T.S.; Benjamin, R.S.; Blay, J.Y.; Bui, B.N.; Collin, F.; Delaney, T.F.; Duffaud, F.; Filleron, T.; Fiore, M.; Gelderblom, H.; George, S.; Grimer, R.; Grosclaude, P.; Gronchi, A.; Haas, R.; Hohenberger, P.; Issels, R.; Italiano, A.; Jooste, V.; Krarup-Hansen, A.; Pechoux, C. le; Mussi, C.; Oberlin, O.; Patel, S.; Piperno-Neumann, S.; Raut, C.; Ray-Coquard, I.; Rutkowski, P.; Schuetze, S.; Sleijfer, S.; Stoeckle, E.; Glabbeke, M. van; Woll, P.; Gourgou-Bourgade, S.; Mathoulin-Pelissier, S.
• Date: 2015-05-31
• Journal: Annals of Oncology
• Volume: 26
• Issue: 5
• Pages: 865 - 872
• DOI: doi:10.1093/annonc/mdu360